[go: up one dir, main page]

MX2023005565A - Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos. - Google Patents

Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos.

Info

Publication number
MX2023005565A
MX2023005565A MX2023005565A MX2023005565A MX2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A
Authority
MX
Mexico
Prior art keywords
tgf
rankl
activin
bifunctional
bone
Prior art date
Application number
MX2023005565A
Other languages
English (en)
Inventor
Hq Han
Xiaolan Zhou
Original Assignee
Hq Han
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hq Han filed Critical Hq Han
Publication of MX2023005565A publication Critical patent/MX2023005565A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta exposición de la invención proporciona nuevas moléculas bifuncionales que comprenden al menos una molécula de unión a RANKL y al menos una molécula de unión a Activina o TGF-ß, que son capaces de secuestrar RANKL y Activina o TGF-ß en paralelo. También se proporcionan composiciones farmacéuticas de tales moléculas antagonistas bifuncionales y sus usos terapéuticos para tratar diversos trastornos óseos cuya patogénesis implica la activación de ambas vías de señalización RANKL-NFkB y Activina/TGFB-Smad2/3, tales como metástasis ósea, pérdida ósea en cáncer, fragilidad ósea en enfermedades neuromusculares, osteogénesis imperfecta, fractura, etc., osteopenia y osteoporosis.
MX2023005565A 2020-11-11 2021-11-05 Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos. MX2023005565A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112380P 2020-11-11 2020-11-11
US202063113922P 2020-11-15 2020-11-15
PCT/US2021/058181 WO2022103660A1 (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005565A true MX2023005565A (es) 2024-02-23

Family

ID=81601668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005565A MX2023005565A (es) 2020-11-11 2021-11-05 Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos.

Country Status (7)

Country Link
EP (1) EP4243931A4 (es)
JP (1) JP2023548346A (es)
KR (1) KR20230118573A (es)
AU (1) AU2021377176A1 (es)
CA (1) CA3197104A1 (es)
MX (1) MX2023005565A (es)
WO (1) WO2022103660A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287028T3 (es) * 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
ES2711213T3 (es) * 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
WO2010097394A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
EP2409990A4 (en) * 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd VARIANT OF A CONSTANT ANTIBODY REGION
ES2869580T3 (es) * 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
PL2542590T5 (pl) * 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
BR112014024398B1 (pt) * 2012-03-31 2022-03-08 R-Pharm International, Llc Polipeptídeo que se liga ao rankl humano, composições terapêuticas compreendendo o dito polipeptídeo, ácido nucleico isolado, vetor de expressão e uso terapêutico do dito polipeptídeo
SG11201503324WA (en) * 2012-11-01 2015-05-28 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014145806A2 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN107636154A (zh) * 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
JOP20190255A1 (ar) * 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
CN111492066A (zh) * 2017-10-20 2020-08-04 国家儿童医疗中心 使用转录本进行抗体方向的方法及由其衍生的组合物
KR20210110818A (ko) * 2018-12-05 2021-09-09 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 Rank 길항제 및 이에 대한 용도

Also Published As

Publication number Publication date
WO2022103660A1 (en) 2022-05-19
JP2023548346A (ja) 2023-11-16
EP4243931A1 (en) 2023-09-20
CA3197104A1 (en) 2022-05-19
AU2021377176A1 (en) 2023-06-22
EP4243931A4 (en) 2025-01-01
KR20230118573A (ko) 2023-08-11

Similar Documents

Publication Publication Date Title
EA201991480A1 (ru) Биспецифические молекулы, связывающиеся со связанным с анти-фно вызывающим апоптоз рецептором 2 лиганда и анти-кадгерином 17 для лечения рака
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
BR112018013827A2 (pt) moduladores de 5?-nucleotidase, ecto e uso dos mesmos
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
NO20054769D0 (no) Substituerte fenylalkansyrer
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
MX2016012716A (es) Compuestos y metodos para suministro trans-membrana de moleculas.
MXPA05011523A (es) Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
UA107783C2 (en) Isoindoline compounds for use in treating cancer
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CY1118081T1 (el) Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
MXPA05011524A (es) Acidos carboxilicos sustituidos.
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2009008096A (es) Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
EA201890198A1 (ru) Новые белки, специфичные в отношении lag-3
TW200630327A (en) Substituted phenylalkanoic acids
JO2645B1 (en) Vehicles
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона